Immunitor's V5 meets TB endpoint

Immunitor Inc. (College Park, Md.) said once-daily oral V5 plus standard of care (SOC) met the primary endpoint of a significantly greater proportion of patients with a negative sputum smear at one month vs. placebo plus SOC in the Phase IIb Study imm01 trial to treat tuberculosis. Specifically, 26 of 27 patients (96.3%) treated with V5 plus SOC had a negative sputum smear compared to 7 of 28 patients (25%) who received placebo plus SOC. V5 is an oral therapeutic vaccine derived from pooled blood of carriers of HBV and HCV. SOC consisted of ethambutol, isoniazid, rifampicin, streptomycin and pyrazinamide. ...